Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?
2025 ASCO Annual Meeting
Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARANOTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients with metastatic hormone-sensitive prostate cancer (Abstract 5004).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
On behalf of the ARASENS investigators, I was very pleased to present the ARASENS quality of life data. ARASENS is a phase three study in patients with metastatic hormone-sensitive prostate cancer. Patients were enrolled and were randomized to ADT plus darolutamide versus ADT and placebo to assess a primary endpoint of radiographic progression-free survival of darolutamide in this setting. Importantly, patients who were enrolled were predominantly high-volume metastatic disease and most had de novo metastatic hormone-sensitive disease. In terms of the quality of life analysis, patients were assessed by the Brief Pain. In the patients treated with ADT plus darolutamide versus ADT alone. I think also importantly the subscales of the FACT-P that were analyzed did suggest that certain subscales were improved more than others including urinary symptoms and prostate cancer-specific symptoms as well as functional well-being and social well-being, suggesting that patients were reporting that they had better time with their families and performing their daily activities. Ultimately, these suggest that darolutamide in the addition to ADT were improving metastatic hormone-sensitive prostate cancer patients' quality of life in addition to being associated with the radiographic progression-free survival advantage for this combination.
The ASCO Post Staff
Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500).
The ASCO Post Staff
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated better efficacy and safety compared with liso-cel monotherapy, with statistically significant differences for complete response rate and overall response rate. In Abstract 7039, patients with R/R CLL/SLL who had received two or more prior lines of therapy had improved response, delayed progression, and prolonged survival with liso-cel compared with a real-world cohort treated with standard-of-care therapy.
The ASCO Post Staff
Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early screening for breast cancer, providing financial assistance, and addressing the disparities Black women face in breast cancer care and outcomes.
The ASCO Post Staff
Sara M. Tolaney, MD, MPH, FASCO, of Dana-Farber Cancer Institute and Harvard Medical School, discusses findings from the phase III ASCENT-04/KEYNOTE-D19 study, which compared sacituzumab govitecan-hziy plus pembrolizumab vs chemotherapy plus pembrolizumab in previously untreated patients with PD-L1–positive advanced triple-negative breast cancer (TNBC) (LBA109).
The ASCO Post Staff
Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, discusses the sensitivity of age and family history criteria for determining eligibility for pancreatic cancer surveillance among individuals with a hereditary risk for the malignancy (Abstract 10500).
